48 related articles for article (PubMed ID: 27917627)
1. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
2. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
3. Novel adenovirus vector-based vaccines for HIV-1.
Barouch DH
Curr Opin HIV AIDS; 2010 Sep; 5(5):386-90. PubMed ID: 20978378
[TBL] [Abstract][Full Text] [Related]
4. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.
Ruane D; Do Y; Brane L; Garg A; Bozzacco L; Kraus T; Caskey M; Salazar A; Trumpheller C; Mehandru S
Mucosal Immunol; 2016 Sep; 9(5):1340-52. PubMed ID: 26732678
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
Koblin BA; Casapia M; Morgan C; Qin L; Wang ZM; Defawe OD; Baden L; Goepfert P; Tomaras GD; Montefiori DC; McElrath MJ; Saavedra L; Lau CY; Graham BS;
PLoS One; 2011; 6(9):e24517. PubMed ID: 21931737
[TBL] [Abstract][Full Text] [Related]
6. Expression of HIV-1 antigens in plants as potential subunit vaccines.
Meyers A; Chakauya E; Shephard E; Tanzer FL; Maclean J; Lynch A; Williamson AL; Rybicki EP
BMC Biotechnol; 2008 Jun; 8():53. PubMed ID: 18573204
[TBL] [Abstract][Full Text] [Related]
7. Heterologous DNA Prime/Protein Boost Immunization Targeting Nef-Tat Fusion Antigen Induces Potent T-cell Activity and in vitro Anti-SCR HIV-1 Effects.
Sadeghi L; Bolhassani A; Mohit E; Baesi K; Aghasadeghi MR
Curr HIV Res; 2024 May; ():. PubMed ID: 38712371
[TBL] [Abstract][Full Text] [Related]
8. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
Hammer SM; Sobieszczyk ME; Janes H; Karuna ST; Mulligan MJ; Grove D; Koblin BA; Buchbinder SP; Keefer MC; Tomaras GD; Frahm N; Hural J; Anude C; Graham BS; Enama ME; Adams E; DeJesus E; Novak RM; Frank I; Bentley C; Ramirez S; Fu R; Koup RA; Mascola JR; Nabel GJ; Montefiori DC; Kublin J; McElrath MJ; Corey L; Gilbert PB;
N Engl J Med; 2013 Nov; 369(22):2083-92. PubMed ID: 24099601
[TBL] [Abstract][Full Text] [Related]
9. IL-17A expression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunization.
Ravichandran J; Jackson RJ; Trivedi S; Ranasinghe C
J Interferon Cytokine Res; 2015 Mar; 35(3):176-85. PubMed ID: 25493691
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost vaccine using antigen-loaded microparticles and adenovirus (encoding antigen) enhances cellular immune responses and antitumor activity.
Ellis AA; Geary SM; Salem AK
Int J Pharm; 2023 May; 638():122932. PubMed ID: 37031810
[TBL] [Abstract][Full Text] [Related]
11. Immunity boost against pancreatic cancer.
Carmona J
Nat Med; 2021 Mar; ():. PubMed ID: 33658709
[No Abstract] [Full Text] [Related]
12. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
[TBL] [Abstract][Full Text] [Related]
13. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.
Andersson AC; Holst PJ
J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
15. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
16. Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.
Chauhan P; Hu S; Prasad S; Sheng WS; Lokensgard JR
Glia; 2021 Apr; 69(4):858-871. PubMed ID: 33128485
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection.
Hosseini Rouzbahani N; Bayanolhagh S; Gholami M; Esmaeilzadeh A; Bayat Jozani Z; Mohraz M; Pourfathollah AA
Iran J Allergy Asthma Immunol; 2016 Oct; 15(5):403-412. PubMed ID: 27917627
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
19. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
